Literature DB >> 8821833

Correlation between Banff classification, acute renal rejection scores and reversal of rejection.

L W Gaber1, L W Moore, R R Alloway, S D Flax, M H Shokouh-Amiri, T Schroder, A O Gaber.   

Abstract

The Banff classification of acute rejection is based on histologic grades and scores for borderline changes, glomerular, vascular, interstitial and tubular lesions. We reviewed 56 episodes of acute rejection occurring in 44 kidney allograft recipients (30 cadaveric and 14 living donor transplants), comparing Banff classification to degree of reversibility of rejection. Rejection reversal was defined as complete if serum creatinine returned < or = 25% of baseline, partial if creatinine was > 25% to < 75% of baseline, and irreversible if creatinine was > or = 75% of baseline or graft loss occurred. Eight biopsies were classified as borderline (SUM score 1.6 +/- 0.5), 14 grade I (SUM score 3.3 +/- 0.4), 19 grade II (SUM score 4.2 +/- 0.3), and 15 grade III (SUM score 8.5 +/- 0.4). SUM distinguished borderline and grade III rejections, but not grades I and II. Clinically, grade and SUM score correlated with rejection reversal. Complete reversal of rejection occurred in 93% of patients with grade I rejection, while 47% of patients with grade III had irreversible rejection. The mean SUM for complete reversal was 3.9 +/- 0.34 and was different from SUM of partial (6.0 +/- 0.86) and irreversible (8.5 +/- 0.93), P < 0.006. Meanwhile, vascular scores were similar for rejections with complete (0.9 +/- 0.2) or partial (1.0 +/- 0.4) reversal, but significantly higher in those with irreversible rejection (3.0 +/- 0.4, P < 0.000). Likewise, mean scores for tubulitis and interstitial inflammation were significantly higher for irreversible rejection. Resolution of rejection by steroids was correlated to low vascular score (steroid sensitive 0.65 +/- 0.25 vs. steroid resistant 1.42 +/- 0.18, P < 0.01), and low SUM score (steroid sensitive 3.7 +/- 0.5 vs. steroid resistant 5.22 +/- 0.43, P < 0.04). Neither scores for tubulitis nor interstitial cellular inflammation were predictive of steroid sensitivity. These data demonstrate that Banff scoring has clinical relevance in predicting rejection reversal and has implications to first-line therapy of rejection episodes.

Entities:  

Mesh:

Year:  1996        PMID: 8821833     DOI: 10.1038/ki.1996.68

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  11 in total

1.  A molecular classifier for predicting future graft loss in late kidney transplant biopsies.

Authors:  Gunilla Einecke; Jeff Reeve; Banu Sis; Michael Mengel; Luis Hidalgo; Konrad S Famulski; Arthur Matas; Bert Kasiske; Bruce Kaplan; Philip F Halloran
Journal:  J Clin Invest       Date:  2010-05-24       Impact factor: 14.808

2.  Intragraft levels of Foxp3 mRNA predict progression in renal transplants with borderline change.

Authors:  Hicham Mansour; Sébastien Homs; Dominique Desvaux; Cécile Badoual; Karine Dahan; Marie Matignon; Vincent Audard; Philippe Lang; Philippe Grimbert
Journal:  J Am Soc Nephrol       Date:  2008-07-30       Impact factor: 10.121

3.  Blocking MHC class II on human endothelium mitigates acute rejection.

Authors:  Parwiz Abrahimi; Lingfeng Qin; William G Chang; Alfred L M Bothwell; George Tellides; W Mark Saltzman; Jordan S Pober
Journal:  JCI Insight       Date:  2016-01-21

4.  Characteristics of alloreactive T cells measured before renal transplantation.

Authors:  P J E J van de Berg; S L Yong; S D Koch; N Lardy; K A M I van Donselaar-van der Pant; S Florquin; F J Bemelman; R A W van Lier; I J M ten Berge
Journal:  Clin Exp Immunol       Date:  2012-05       Impact factor: 4.330

5.  Raman spectroscopic differentiation of activated versus non-activated T lymphocytes: an in vitro study of an acute allograft rejection model.

Authors:  Kristian L Brown; Olena Y Palyvoda; Jagdish S Thakur; Sandra L Nehlsen-Cannarella; Omar R Fagoaga; Scott A Gruber; Gregory W Auner
Journal:  J Immunol Methods       Date:  2008-11-06       Impact factor: 2.303

6.  Treatment of acute kidney allograft rejection with a non-mitogenic CD3 antibody.

Authors:  R T Meijer; S Surachno; S L Yong; F J Bemelman; S Florquin; I J M Ten Berge; P T A Schellekens
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

Review 7.  Efficacy of Acute Cellular Rejection Treatment According to Banff Score in Kidney Transplant Recipients: A Systematic Review.

Authors:  Caroline Lamarche; Jean-Maxime Côté; Lynne Sénécal; Héloïse Cardinal
Journal:  Transplant Direct       Date:  2016-11-15

8.  The Effect of Histological CD20-Positive B Cell Infiltration in Acute Cellular Rejection on Kidney Transplant Allograft Survival.

Authors:  Yan Jiang; Rending Wang; Huiping Wang; Hongfeng Huang; Wenhan Peng; Wenxian Qiu; Jingyi Zhou; Jianghua Chen
Journal:  J Immunol Res       Date:  2016-12-12       Impact factor: 4.818

9.  Plasma cell-rich acute rejection of the renal allograft: A distinctive morphologic form of acute rejection?

Authors:  R Gupta; A Sharma; P J Mahanta; S K Agarwal; A K Dinda
Journal:  Indian J Nephrol       Date:  2012-05

10.  Association of medication non-adherence with short-term allograft loss after the treatment of severe acute kidney transplant rejection.

Authors:  Ahmed Al-Sheyyab; Laura Binari; Mohammed Shwetar; Everly Ramos; Meghan E Kapp; Stefanie Bala; Nikita Wilson; Rachel C Forbes; J Harold Helderman; Khaled Abdel-Kader; Beatrice P Concepcion
Journal:  BMC Nephrol       Date:  2019-10-17       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.